COMBOGESIC IV Drug Patent Profile

When do Combogesic Iv patents expire, and what generic alternatives are available?

Combogesic Iv is a drug marketed by Hikma and is included in one NDA. There are six patents protecting this drug.

This drug has seventy patent family members in thirty-one countries.

The generic ingredient in COMBOGESIC IV is acetaminophen; ibuprofen sodium. There are sixty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the acetaminophen; ibuprofen sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Combogesic Iv

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 17, 2026. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for COMBOGESIC IV

International Patents:	70
US Patents:	6
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for COMBOGESIC IV

COMBOGESIC IV is protected by ten US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW PRODUCT.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	COMBOGESIC IV	acetaminophen; ibuprofen sodium	SOLUTION;INTRAVENOUS	215320-001	Oct 17, 2023		RX	Yes	Yes	12,220,392
Hikma	COMBOGESIC IV	acetaminophen; ibuprofen sodium	SOLUTION;INTRAVENOUS	215320-001	Oct 17, 2023		RX	Yes	Yes	11,896,567
Hikma	COMBOGESIC IV	acetaminophen; ibuprofen sodium	SOLUTION;INTRAVENOUS	215320-001	Oct 17, 2023		RX	Yes	Yes	12,083,087

International Patents for COMBOGESIC IV

See the table below for patents covering COMBOGESIC IV around the world.

Country	Patent Number	Title	Estimated Expiration
Singapore	189319	A COMBINATION COMPOSITION
World Intellectual Property Organization (WIPO)	2012060719
Mexico	367209	UNA COMPOSICIÓN INTRAVENOSA QUE COMPRENDE IBUPROFENO Y PARACETAMOL EN COMBINACIÓN. (A COMBINATION COMPOSITION.)

Investment Scenario, Market Dynamics, and Financial Trajectory for COMBOGESIC IV

Last updated: February 3, 2026

Executive Summary

COMBOGESIC IV is a proprietary injectable combination analgesic containing a fixed-dose formulation of ibuprofen and paracetamol, designed for intravenous administration. It is positioned within the acute pain management segment, targeting hospital use and surgical settings. This report analyzes its potential market landscape, competitive environment, regulatory considerations, and projected financial trajectory to aid strategic investment decisions.

---

I. Product Overview and Market Positioning

Product Description	Composition	Dosage Form	Route of Administration	Indications	Status
Ibuprofen + Paracetamol	Intravenous (IV)	IV infusion	Moderate to severe pain	Under clinical trials / Regulatory review

Key Features & Differentiators

• Fixed-dose combination enabling rapid pain relief
• Suitable for patients intolerant to oral medications
• Hospital and surgical use emphasis

Current Development Stage

• Undergoing Phase III clinical trials (per latest pipeline updates)
• Regulatory submissions expected in select markets by 2023–2024

---

II. Market Dynamics

A. Market Size and Growth Outlook

Market Segment	2022 Global Market Size (USD)	CAGR (2023–2028)	Forecast 2028 (USD)	Comments
IV Pain Management	5.3 billion	6.2%	7.9 billion	Growing demand in hospitals for rapid IV analgesia
Postoperative Pain	2.8 billion	5.8%	3.8 billion	Increasing surgical procedures globally
Critical Care Pain	1.1 billion	4.5%	1.4 billion	Elevated need in ICU settings

Sources: MarketsandMarkets [1], Grand View Research [2]

B. Key Market Drivers

• Rising prevalence of acute pain conditions (postoperative, trauma-related)
• Growth in surgical procedures (e.g., orthopedics, cardiovascular, neurosurgery)
• Increasing adoption of hospital-based IV opioids sparingly, due to opioid-sparing initiatives
• Expanding healthcare infrastructure in emerging markets

C. Market Challenges

• Regulatory hurdles in obtaining approval across diverse jurisdictions
• Competition from existing IV analgesics (ketorolac, morphine, fentanyl)
• Concerns regarding NSAID-related adverse events (renal, gastrointestinal)

---

III. Competitive Landscape

A. Major Competitors and Alternatives

Competitor / Product	Composition	Strengths	Weaknesses	Market Share (%)	Regulatory Status
Toradol (ketorolac)	Ketorolac	Well-established efficacy, broad approval	NSAID-related GI and renal risks, limited in some markets	~25	Approved globally
Morphine	Opioid	Potent analgesic	Risk of respiratory depression, dependency	~20	Approved globally
Fentanyl	Opioid	Potent, fast-acting	High abuse potential	~15	Approved globally
NSAID + Paracetamol formulations	Oral	Established use	Limited IV options	N/A	Various

COMBOGESIC IV's competitive advantage hinges on being a fixed-dose, rapid-onset, opioid-sparing IV analgesic with potentially fewer adverse effects compared to opioids, and improved safety over NSAIDs alone.

B. Patent and Regulatory Outlook

• Patent protection anticipated until 2030–2035, depending on jurisdiction
• Regulatory approval pathways may vary: 510(k) or PMA in the U.S., centralized procedure in the EU, fast-track options available in some markets

---

IV. Financial Trajectory and Investment Potential

A. Revenue Projections

Year	Estimated Revenue (USD Millions)	Assumptions
2024	50–80	Initial market entry in select hospitals
2025	150–200	Expanding to more hospitals, increasing prescriber awareness
2026	300–400	Broader geographic approvals, adoption in multiple surgical fields
2027+	500+	Market penetration saturation, potential for global launch

Note: Assumes 20% market share of targeted IV pain management markets in developed regions

B. Cost Structure & Investment Needs

• R&D costs: Estimated $50–75 million for completion of trials and regulatory filings
• Manufacturing: Scaling up aseptic fill-finish capacities, estimated at $30 million initial CapEx
• Market Access & Launch: Marketing, education, and distribution estimated at $20 million per major market

C. ROI Analysis

Investment Component	Estimated Cost (USD Millions)	Timeline	Returns
R&D & Regulatory	75	2022–2024	Market entry in 2024
Manufacturing setup	30	2023–2024	Supply readiness
Commercial launch	20 per region	2024 onwards	Revenue buildup

Potential for break-even within 3–4 years post-launch, with high-margin potential given differentiator status and hospital payers' willingness to adopt new analgesics.

---

V. Market Entry Strategies and Regulatory Considerations

A. Regulatory Approaches

Region	Pathway	Key Considerations	Estimated Timeline
United States	510(k) via prior approval	Demonstrate substantial equivalence, safety	18–24 months
European Union	Centralized Marketing Authorization	Leveraging EMA guidelines	12–18 months
Japan	Standard approval + PMDA review	Local clinical data critical	24–36 months

B. Market Access & Reimbursement Strategies

• Engage early with payers, emphasizing reduced opioid use and improved safety profile
• Highlight data from Phase III trials on efficacy and safety
• Conduct health economics and outcomes research (HEOR) to support formulary inclusion

C. Commercialization Risks

• Delays in approval processes
• Market reluctance to shift from established protocols
• Competitive responses from entrenched analgesic providers

---

VI. Comparative Analysis with Existing Therapeutics

Aspect	COMBOGESIC IV	Existing IV NSAIDs / Opioids	Advantages / Disadvantages
Onset of Action	Rapid	Varies	Faster onset enhances patient comfort
Pain Relief Duration	Controlled	Varies	Consistency critical in acute settings
Adverse Event Profile	Potentially lower GI / respiratory risks	Higher GI or respiratory risks	Positioning as safer alternative
Cost per Dose	Anticipated high	Lower	Premium pricing possible, justified by safety

---

Key Takeaways

• COMBOGESIC IV aims to carve a niche in hospital-based IV pain management, focusing on acute, moderate-to-severe pain episodes.
• Market growth projections support a robust opportunity, driven by surgical volume increases and a shift towards opioid-sparing analgesia.
• Competitive landscape features entrenched NSAIDs and opioids; COMBOGESIC IV’s differentiated safety and rapid onset could offer substantial market leverage.
• Estimated revenue potential reaches USD 500 million+ within 5 years of launch, assuming successful regulatory approval and broad adoption.
• Critical success factors include navigating complex regulatory pathways, demonstrating clear safety advantages, and establishing hospital-based formulary inclusion.

---

FAQs

Q1: What are the primary legal and regulatory hurdles for COMBOGESIC IV?
A1: Regulatory challenges include demonstrating safety and efficacy through extensive clinical trials, meeting specific regional requirements, and securing timely approvals, especially in markets with stringent drug validation processes such as the US and EU.

Q2: How does COMBOGESIC IV differentiate itself from existing IV analgesics?
A2: Its fixed-dose combination of ibuprofen and paracetamol provides rapid analgesia with a potentially better safety profile compared to opioids or NSAIDs alone, aiming to reduce adverse gastrointestinal, renal, and respiratory risks.

Q3: What is the competitive advantage of COMBOGESIC IV in hospital pain management?
A3: The drug offers fast-onset pain relief suitable for postoperative and acute pain, with an opioid-sparing mechanism, and is designed for intravenous administration, making it ideal for use in settings requiring prompt analgesia.

Q4: What is the timeline for market entry and ROI realization?
A4: Regulatory approval is projected between 2023–2024, with initial revenues beginning in 2024. Break-even is expected within 3–4 years post-launch, with significant growth potential thereafter.

Q5: Which markets should be prioritized for initial launch?
A5: High-priority markets include the United States, European Union, and Japan, given their advanced healthcare infrastructure, robust hospital systems, and receptive regulatory environments. Emerging markets should follow after establishing proof of concept.

---

References

[1] MarketsandMarkets, “Pain Management Market,” 2022.
[2] Grand View Research, “IV Analgesics Market,” 2022.